Exec-Edge – Page 77 – ExecEdge

Ventus Therapeutics Begins Phase 1 Trial of Neuroinflammation Treatment

Ventus Therapeutics Begins Phase 1 Trial of Neuroinflammation Treatment

By Exec Edge Editorial Staff Ventus Therapeutics said it initiated Phase 1 testing for VENT-02, an orally administered NLRP3 inhibitor with remarkable brain penetration. The trial with healthy volunteers aims to explore VENT-02’s impact on neuroinflammatory diseases, such as Parkinson’s...

Comera Study Shows Caffeine’s Ability to Reduce Viscosity in Antibodies

Comera Study Shows Caffeine’s Ability to Reduce Viscosity in Antibodies

By Daniella Parra Comera Life Sciences Holdings (Nasdaq: CMRA) said it published data showing caffeine’s potential to reduce viscosity in subcutaneous formulations of monoclonal antibodies. The studies demonstrated caffeine’s positive influence on pharmacokinetics and its compatibility with monoclonal antibody ipilimumab,...

TechMet Reports Closing of $200 Million Equity Raise

TechMet Reports Closing of $200 Million Equity Raise

By Daniella Parra TechMet said it closed its latest $200 million equity fundraising round and is set to exceed a billion-dollar valuation in the next few months. The global critical minerals investment company said the funds will help develop and...

Input your search keywords and press Enter.